CAR‐T Cells: Future Perspectives

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

“…The most prominent successes of CAR-T cell therapy have been documented in hematological cancers with the FDA approvals of Kymriah® and Yescarta®, two second-generation CAR-T cell products targeting the B-cell antigen CD19 [NCT02435849, NCT02445248, NCT02348216] (46,(48)(49)(50). Since these ground-breaking approvals, additional antigenic targets in hematological malignancies have demonstrated promise in ongoing CAR-T cell therapy clinical trials including B cell maturation antigen (BCMA), CD20, CD22, CD30, CD33, CD38, CD123, and CD138 (56)(57)(58).…”

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?

“…Future work will concentrate on safely tuning the efficacy of CAR T-cells against tumor cells, whilst avoiding on-target off-tumor toxicities, and on limiting the emergence of tumor escape variants from selective antigen pressure given by single CAR approaches. Responses to these new challenges will be provided by means of smarter CARs, entailing double targeting approaches (dual CARs) and fourth generation armored CARs designed to secrete cytokines, together with combinatorial strategies with other immunomodulatory agents (i.e., checkpoint inhibitors) [96,97]. In this perspective, non-viral transposon procedures can benefit from their increased DNA carrying capacity.…”

Proyecto RET-A: Reflexión Estratégica para el manejo e implementación de las nuevas terapias avanzadas en España

“…Más allá de este análisis específico, merece especial atención un estudio publicado por la Asociación Europea de Hematología, donde se analizaron los ensayos clínicos registrados en ClinicalTrial.gov (en este caso, hasta el 7 de diciembre de 2018). En el estudio se analizaron 385 ensayos clínicos, concluyendo que el desarrollo de ensayos clínicos en CAR-T se han incrementado considerablemente desde 2016 (Figura 15) y que un tercio de los estudios en marcha están centrados en el antígeno tumoral CD19 95 : aspectos relevantes en terapias CAR-T EHA: Asociación Europea de Hematología…”